JPH01236062A - Accessory thyroid hormone removing membrane - Google Patents
Accessory thyroid hormone removing membraneInfo
- Publication number
- JPH01236062A JPH01236062A JP63064208A JP6420888A JPH01236062A JP H01236062 A JPH01236062 A JP H01236062A JP 63064208 A JP63064208 A JP 63064208A JP 6420888 A JP6420888 A JP 6420888A JP H01236062 A JPH01236062 A JP H01236062A
- Authority
- JP
- Japan
- Prior art keywords
- membrane
- pore radius
- active layer
- parathyroid hormone
- polymer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012528 membrane Substances 0.000 title claims abstract description 31
- 239000005495 thyroid hormone Substances 0.000 title abstract 4
- 229940036555 thyroid hormone Drugs 0.000 title abstract 4
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 title abstract 2
- 239000011148 porous material Substances 0.000 claims abstract description 20
- 102000003982 Parathyroid hormone Human genes 0.000 claims description 33
- 108090000445 Parathyroid hormone Proteins 0.000 claims description 33
- 239000000199 parathyroid hormone Substances 0.000 claims description 33
- 229960001319 parathyroid hormone Drugs 0.000 claims description 33
- 238000000502 dialysis Methods 0.000 abstract description 14
- 229920000642 polymer Polymers 0.000 abstract description 6
- 239000002904 solvent Substances 0.000 abstract description 5
- 230000008014 freezing Effects 0.000 abstract description 3
- 238000007710 freezing Methods 0.000 abstract description 3
- 238000009833 condensation Methods 0.000 abstract description 2
- 230000005494 condensation Effects 0.000 abstract description 2
- 238000001816 cooling Methods 0.000 abstract description 2
- 238000009987 spinning Methods 0.000 abstract description 2
- 239000002861 polymer material Substances 0.000 abstract 1
- 239000008280 blood Substances 0.000 description 14
- 210000004369 blood Anatomy 0.000 description 14
- 239000012510 hollow fiber Substances 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 6
- 239000004926 polymethyl methacrylate Substances 0.000 description 6
- 239000002207 metabolite Substances 0.000 description 5
- 208000020084 Bone disease Diseases 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 230000015271 coagulation Effects 0.000 description 4
- 238000005345 coagulation Methods 0.000 description 4
- 238000000113 differential scanning calorimetry Methods 0.000 description 4
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 3
- 229910001424 calcium ion Inorganic materials 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002301 cellulose acetate Polymers 0.000 description 2
- 239000000112 cooling gas Substances 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000001631 haemodialysis Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000000322 hemodialysis Effects 0.000 description 2
- 229920006158 high molecular weight polymer Polymers 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 210000004898 n-terminal fragment Anatomy 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 239000007818 Grignard reagent Substances 0.000 description 1
- 206010018873 Haemoconcentration Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000001112 coagulating effect Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000004807 desolvation Methods 0.000 description 1
- 235000020805 dietary restrictions Nutrition 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 150000004795 grignard reagents Chemical class 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- 229920002239 polyacrylonitrile Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000010526 radical polymerization reaction Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- 229940021056 vitamin d3 Drugs 0.000 description 1
Landscapes
- Separation Using Semi-Permeable Membranes (AREA)
- External Artificial Organs (AREA)
Abstract
Description
【発明の詳細な説明】
［産業上の利用分野］
本発明は血液中の副甲状腺ホルモンを除去する膜に関す
るものであり、さらに詳しくは血液を浄化するにあたっ
て、特に副甲状腺ホルモンを選択的に除去する膜に関す
るものである。[Detailed Description of the Invention] [Industrial Application Field] The present invention relates to a membrane that removes parathyroid hormone from blood, and more specifically, to a membrane that selectively removes parathyroid hormone in blood purification. It is related to membranes that
［従来の技術］
透析患者の長期合併症はいくつかある力釈その中で重要
かつ緊急の改善を要するものとして骨障害が挙げられる
。[Prior Art] Among the many long-term complications of dialysis patients, bone disorders are one of the most important and require urgent improvement.
この改善・予防のため、骨形成促進のための活性型ビタ
ミンＤ３の投与、透析液のカルシウム濃度の至適化、食
餌制限、血液透析におけるリン除去の至適化など種々の
試みがなされているが、まだ十分といえる段階には至っ
ていない。これら種々の試みの中で、副甲状腺ホルモン
も研究の話題となったことはあるが、その体内蓄積の程
度や除去については、明確な指針が得られていなかった
。Various attempts have been made to improve and prevent this, including administering active vitamin D3 to promote bone formation, optimizing the calcium concentration of dialysate, dietary restrictions, and optimizing phosphorus removal during hemodialysis. However, it has not yet reached the stage where it can be said to be sufficient. Among these various attempts, parathyroid hormone has also become a topic of research, but no clear guidelines have been obtained regarding the extent of its accumulation in the body or its removal.
副甲状腺ホルモンは、血中のカルシウムイオン濃度を調
節するホルモンであり、一般には血中のカルシウムイオ
ン濃度が低下すると、この副甲状腺ホルモンが産生され
、骨からカルシウムを溶出させて血中のカルシウムイオ
ン濃度を一定化させるものである。Parathyroid hormone is a hormone that regulates the concentration of calcium ions in the blood. Generally, when the concentration of calcium ions in the blood decreases, parathyroid hormone is produced, leaching calcium from bones and increasing the amount of calcium ions in the blood. This stabilizes the concentration.
［発明が解決しようとする課題］
本発明者らは、副甲状腺ホルモンについて鋭意研究した
結果、透析患者には透析を始めて２年程度で、副甲状腺
ホルモンが蓄積すること、特に副甲状腺ホルモンの中間
代謝産物は健常者に比べて２０〜３０倍も蓄積している
こと、この副甲状腺ホルモンはセルロース膜で代表され
る通常の透析膜では除去しえないことを見出した。副甲
状腺ホホルモンの異常蓄積が、骨障害の一因となること
は容易に推測され、これを除去することにより骨障害を
抑制し得ることが期待される。本発明は透析患者の体内
に蓄積される副甲状腺ホルモンの効果的な選択除去膜を
提供することを目的とする。[Problems to be Solved by the Invention] As a result of intensive research on parathyroid hormone, the present inventors have found that parathyroid hormone accumulates in dialysis patients within about two years after starting dialysis, and that, in particular, parathyroid hormone accumulates in dialysis patients. They found that metabolites accumulate 20 to 30 times more than in healthy individuals, and that this parathyroid hormone cannot be removed by ordinary dialysis membranes, typically cellulose membranes. It is easily assumed that abnormal accumulation of parathyroid hormone is a cause of bone disorders, and it is expected that bone disorders can be suppressed by removing this. An object of the present invention is to provide a membrane that effectively selectively removes parathyroid hormone accumulated in the body of a dialysis patient.
［課題を解決するための手段］ 上記の目的は、以下の本発明により達成される。[Means to solve the problem] The above object is achieved by the present invention as follows.
すなわち本発明は、活性層における細孔半径が３０〜８
０人である副甲状腺ホルモン除去膜である。That is, in the present invention, the pore radius in the active layer is 30 to 8.
This is a parathyroid hormone removal membrane for 0 people.
本発明でいう活性層における細孔半径とは、対称膜の場
合はＤＳＣ（示差走査熱量）測定によって、細孔径中の
水の毛管凝縮による氷点降下度を測ることによって求め
られる（ 「Ｍｅｍｂｒａｎｅｓ ａｎｄｍｅｍｂｒａ
ｎｅ ｐｒｏｃｅｓｓｅｓＪ １）５０７ Ｐｌｅｎ
ｕｍ １）ｒｅＳＳ、 ＮｅＷＹｏｒｋ、 １９８Ｂ）
。また非対称膜は、水の透過実験を行なって細孔理論（
ｐｏｒｅ ｔｈｅｏｒｙ）から求めることができる（
ｒ Ｍｅｍｂｒａｎｅｓ ａｎｄ ｍｅｍｂｒａｎｅ
ｐｒｏｃｅｓｓｅｓ」１）５０７ ＰｌｅｎｌＪｍ １
）ｒｅｓｓ、 ＮｅＷ ＹＯｒｋ、 １９８６）。In the present invention, the pore radius in the active layer is determined by DSC (differential scanning calorimetry) measurement in the case of a symmetric membrane, and by measuring the degree of freezing point depression due to capillary condensation of water in the pore diameter ("Membranes and Membranes").
ne processesJ 1) 507 Plen
um 1) reSS, NewYork, 198B)
. In addition, water permeation experiments were conducted on asymmetric membranes, and pore theory (
pore theory) can be found from (
r Membranes and membranes
1) 507 PlenlJm 1
) res, New York, 1986).
細孔径の大小によって水の氷点が変化することを利用し
たＤＳＣ法は、水中に浸漬してあった中空糸試料の内外
表面の付着水を除いた後、約５胴の長さのもの数１０本
を密閉パンにつめて秤量し、示差走査熱量計（Ｐｅｒｋ
ｉｎ−Ｅ１ｍｃｒ社製、” Ｄ Ｓ Ｃ−２Ｃ”）にか
ける。試料は一４５°Ｃに冷却してから、２，５°Ｃ／
ｍｉｎの昇温速度で加温して測定する。The DSC method, which utilizes the fact that the freezing point of water changes depending on the size of the pores, uses hollow fiber samples that have been immersed in water to remove adhering water from the inner and outer surfaces of the sample, and then remove the water from the hollow fiber sample, which has a length of about 5 to 10. Weigh the books in an airtight pan and use a differential scanning calorimeter (Perk).
in-E1mcr, "DSC-2C"). The sample was cooled to -45°C and then heated to 2.5°C/
Measurement is performed by heating at a heating rate of min.
このようにしてＤＳＣ測定をすると、細孔半径に応じた
温度にピークをもつ融解曲線が得られ、この融解曲線か
ら容易に細孔半径を求めることができる。When DSC measurement is performed in this manner, a melting curve having a peak at a temperature corresponding to the pore radius is obtained, and the pore radius can be easily determined from this melting curve.
細孔半径があまりにも小さい場合は、当然のことながら
副甲状腺ホルモンは除去できず、細孔半径３０大が必要
である。細孔半径が大きくなり過ぎると、生体に有用な
タンパクが除去されて問題となるので、細孔半径８０人
が限度である。従って、副甲状腺ホルモン除去膜として
の適切な活性層における細孔半径は３０〜８０人、好ま
しくは３０〜５５大のものが用いられる。Naturally, if the pore radius is too small, parathyroid hormone cannot be removed, and a pore radius of 30 mm is required. If the pore radius becomes too large, proteins useful to the living body will be removed, causing problems, so the pore radius is limited to 80. Therefore, the pore radius of the active layer suitable for use as a parathyroid hormone removal membrane is 30 to 80, preferably 30 to 55.
本発明でいう副甲状腺ホルモンは、それ自体のみでなく
その中間代謝産物も含むことを意味する。Parathyroid hormone as used in the present invention includes not only itself but also its intermediate metabolites.
透析患者の体内に蓄積される副甲状腺ホルモンは、この
中間代謝産物の占める割合が大きく、特にＮ末端フラグ
メント以外の中間代謝産物の占める割合が大きい。The parathyroid hormone accumulated in the body of a dialysis patient consists of a large proportion of these intermediate metabolites, and in particular, a large proportion of intermediate metabolites other than the N-terminal fragment.
本発明の除去膜は副甲状腺ホルモン（ＰＴＨ）、特に透
析患者の体内に蓄積される副甲状腺ホルモンを選択的に
除去することができ、下記式（１）で表わされる血中濃
度変化率を７０％以下にすることができる。The removal membrane of the present invention can selectively remove parathyroid hormone (PTH), especially parathyroid hormone accumulated in the body of dialysis patients, and can reduce the blood concentration change rate expressed by the following formula (1) by 70. % or less.
血中ＰＴＨ濃度変化率（％）−
透析後の血中ＰＴＨ濃度
□×１００・・・・・・（１）
透析前の血中ＰＴＨ濃度
副甲状腺ホルモンの血中濃度は、ＰＴＨキット「ヤマサ
」 （ヤマサ醤油■製）を用いて、測定することができ
る。該キットは、副甲状腺ホルモン、およびそれのＮ末
端フラグメントを除くほとんどの中間代謝産物を測定す
ることができるキットである。Blood PTH concentration change rate (%) - Blood PTH concentration after dialysis □ x 100... (1) Blood PTH concentration before dialysis The blood concentration of parathyroid hormone is determined by the PTH kit "Yamasa" (manufactured by Yamasa Soy Sauce ■). The kit is capable of measuring parathyroid hormone and most of its intermediate metabolites except the N-terminal fragment.
本発明の除去膜の素材としては、血液透析、血液−適用
に供される高分子重合体が用いられる。As the material for the removal membrane of the present invention, a high molecular weight polymer used for hemodialysis and blood applications is used.
具体的には、ポリメチルメタクリレート、ポリアクリロ
ニトリル、セルロース、酢酸セルロース、ポリスルホン
、ポリビニルアルコール、あるいはポリビニルアルコー
ルとエチレンの共重合体のようなビニルアルコール共重
合体などが挙げられるが、特にこれに限定されない。好
ましくはポリメチルメタクリレート、酢酸セルロースで
あり、より好ましくはポリメチルメタクリレートである
。Specific examples include, but are not limited to, polymethyl methacrylate, polyacrylonitrile, cellulose, cellulose acetate, polysulfone, polyvinyl alcohol, and vinyl alcohol copolymers such as a copolymer of polyvinyl alcohol and ethylene. . Preferred are polymethyl methacrylate and cellulose acetate, more preferred is polymethyl methacrylate.
膜モジュールの形態としては特に限定するものではない
が、たとえば中空繊維型や平膜積層型が用いられる。Although the form of the membrane module is not particularly limited, for example, a hollow fiber type or a flat membrane laminated type may be used.
本発明の除去膜の特性を得るには、上記高分子重合体を
該重合体の溶媒に溶解し、環状口金から水系凝固洛中に
紡糸して透過性中空糸をつくるに際して、高分子溶液濃
度、凝固・固化に際しての冷却条件、脱溶媒速度を調整
して膜組織を形成させる。たとえば、宗すメチルメタク
リレ−１へ系重合体を膜素材として用いて中空系状の膜
を製造する場合は、ポリマー濃度が２０ｗｔ％ないし３
０ｗｔ％になるようにジメチルスルホキシドなどの溶媒
−〇 −
に溶解する。この溶液を環状紡糸口金から吐出して中空
繊維を形成せしめるに際し、内側から乾燥窒素ガスを導
入し、外側から冷却気体を吹きつけて、中空繊維を形成
せしめる。この際、冷却気体は乾燥温度５〜１７℃、含
有水分の尺度である露点は０〜１０°Ｃであることが好
ましい。次いで、水を主体とした凝固浴に導いて固化、
脱溶媒する。In order to obtain the properties of the removal membrane of the present invention, when the above-mentioned high molecular weight polymer is dissolved in a solvent for the polymer and spun into an aqueous coagulation machine from an annular spinneret to produce a permeable hollow fiber, the concentration of the polymer solution, A film structure is formed by adjusting the cooling conditions and desolvation rate during coagulation and solidification. For example, when producing a hollow membrane using a methyl methacrylate-1 polymer as a membrane material, the polymer concentration is between 20wt% and 3% by weight.
Dissolve in a solvent such as dimethyl sulfoxide to a concentration of 0 wt%. When this solution is discharged from an annular spinneret to form hollow fibers, dry nitrogen gas is introduced from the inside and cooling gas is blown from the outside to form the hollow fibers. At this time, the drying temperature of the cooling gas is preferably 5 to 17°C, and the dew point, which is a measure of the moisture content, is preferably 0 to 10°C. Next, it is introduced into a water-based coagulation bath and solidified.
Remove solvent.
このときの凝固浴温度は１０°Ｃないし２５℃とするこ
とが好ましい。The coagulation bath temperature at this time is preferably 10°C to 25°C.
［実 施 例］
以下、本発明の効果を実施例をもって具体的に説明する
。[Examples] Hereinafter, the effects of the present invention will be specifically explained using examples.
実施例１
グリニア試薬で重合したアイソタクチックポリメチルメ
タクリレート１７５部とラジカル重合法で得たシンジオ
タクチックポリメチルメタクリレート８７５部を、２６
０部のジメチルスルホキシドに溶解した紡糸原液を環状
紡糸口金の外部から吐出し、１０℃の湿潤空気を吹きつ
けて中空糸を形成した。この糸条を２０℃の水中で凝固
脱溶媒させることによって内径２４５μ、外径３０５μ
の中空糸を得た。この中空糸を７５００本束ねて有効面
積１．０ｎ−Ｉ’のモジュールを作成した。Example 1 175 parts of isotactic polymethyl methacrylate polymerized with a Grignard reagent and 875 parts of syndiotactic polymethyl methacrylate obtained by a radical polymerization method were combined into 26 parts of
A spinning dope dissolved in 0 parts of dimethyl sulfoxide was discharged from the outside of the annular spinneret, and humid air at 10° C. was blown thereto to form hollow fibers. By coagulating and desolventizing this yarn in water at 20°C, it has an inner diameter of 245μ and an outer diameter of 305μ.
A hollow fiber was obtained. A module with an effective area of 1.0 n-I' was created by bundling 7,500 of these hollow fibers.
膜構造は均一膜に属しており、平均細孔半径は４０人て
゛あった。The membrane structure belonged to a homogeneous membrane, and the average pore radius was 40.
このようにして試作した透析器を用いて臨床テストを行
なった。副甲状腺ホルモンの透析前・後の値を、ＰＴＨ
キット「ヤマサ」 （ヤマサ醤油■製）を用いて測定し
、血中濃度変化率を求めた。A clinical test was conducted using the dialyzer prototyped in this way. Parathyroid hormone values before and after dialysis, PTH
It was measured using the kit "Yamasa" (manufactured by Yamasa Soy Sauce ■), and the rate of change in blood concentration was determined.
その結果、血中濃度変化率は５１％（ｎ＝１３の平均）
となり、明らかに副甲状腺ホルモンが除去できることが
わかる。As a result, the rate of change in blood concentration was 51% (average of n = 13)
This clearly shows that parathyroid hormone can be removed.
比較例１
平均細孔半径が２０人のポリメチルメタクリレートの中
空糸で作成した透析器（商品名” Ｂ ２−１００’”
東し■製〉を用いて臨床テストを行なった。Comparative Example 1 Dialyzer made of hollow fibers of polymethyl methacrylate with an average pore radius of 20 (trade name: "B 2-100'")
A clinical test was conducted using Toshi ■.
副甲状腺ホルモンの血中濃度変化率は９７％（ｎ−７の
平均）であった。水分の除去による血液濃縮を考慮して
も、副甲状腺ホルモンはあまり除去されていないことが
わかる。The rate of change in blood concentration of parathyroid hormone was 97% (average of n-7). It can be seen that even if hemoconcentration due to water removal is considered, parathyroid hormone is not significantly removed.
［発明の効果］
本発明の除去膜は、副甲状腺ホルモン、特に透析患者の
体内に蓄積される副甲状腺ホルモンを効果的に除去する
ことができる。従って、骨障害の予防・治療に有用とな
り得る。[Effects of the Invention] The removal membrane of the present invention can effectively remove parathyroid hormone, particularly parathyroid hormone accumulated in the body of a dialysis patient. Therefore, it may be useful for prevention and treatment of bone disorders.
Claims (1)
甲状腺ホルモン除去膜。(1) A parathyroid hormone removal membrane having a pore radius of 30 to 80 Å in the active layer.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP63064208A JPH0622617B2 (en) | 1988-03-16 | 1988-03-16 | Parathyroid hormone removal membrane |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP63064208A JPH0622617B2 (en) | 1988-03-16 | 1988-03-16 | Parathyroid hormone removal membrane |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH01236062A true JPH01236062A (en) | 1989-09-20 |
| JPH0622617B2 JPH0622617B2 (en) | 1994-03-30 |
Family
ID=13251430
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP63064208A Expired - Lifetime JPH0622617B2 (en) | 1988-03-16 | 1988-03-16 | Parathyroid hormone removal membrane |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH0622617B2 (en) |
-
1988
- 1988-03-16 JP JP63064208A patent/JPH0622617B2/en not_active Expired - Lifetime
Non-Patent Citations (1)
| Title |
|---|
| CONTR.NEPHROL=1985 * |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0622617B2 (en) | 1994-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1294745C (en) | Asymmetrical microporous hollow fiber for hemodialysis and a process for manufacturing such fibers | |
| US4459210A (en) | Porous membrane | |
| JPH0642905B2 (en) | Hemodialysis membrane | |
| US5290448A (en) | Polyacrylonitrile membrane | |
| JPH10108907A (en) | Membrane for hemocatharsis, its preparation and module for hemocatharsis | |
| JP3714686B2 (en) | Polysulfone-based hollow fiber membrane and method for producing the same | |
| JPH01236062A (en) | Accessory thyroid hormone removing membrane | |
| EP0092587B1 (en) | Polymethyl methacrylate hollow yarn ultra-filtration membrane and process for its production | |
| JP4055634B2 (en) | Hemodialysis membrane and method for producing the same | |
| JPH0970431A (en) | Production of polysulfone hollow fiber type artificial kidney and artificial kidney | |
| JP2873967B2 (en) | Polyacrylonitrile-based hollow fiber membrane and method for producing the same | |
| JP3020016B2 (en) | Hollow fiber membrane | |
| JP4076144B2 (en) | Method for producing hollow fiber membrane and hollow fiber membrane | |
| JP3424807B2 (en) | Hollow fiber membrane | |
| Seita et al. | Polyether‐segmented nylon hemodialysis membranes. I. Preparation and permeability characteristics of polyether‐segmented nylon 610 hemodialysis membrane | |
| JPH07289866A (en) | Polysulfone-based selective permeable membrane | |
| JP3995228B2 (en) | Hollow fiber membrane for blood purification | |
| JP4386607B2 (en) | Polysulfone blood purification membrane production method and polysulfone blood purification membrane | |
| JP4381022B2 (en) | Hollow fiber blood purification membrane | |
| JPH0938473A (en) | Production of polysulfone-base porous hollow fiber membrane | |
| JPH03254826A (en) | Preparation of polysulfone semipermeable membrane | |
| JP2000210544A (en) | Production of semipermeable membrane | |
| JP2005065725A (en) | Hollow fiber blood purifying membrane | |
| JPH0362447B2 (en) | ||
| KR920000560B1 (en) | Hollow fiber membranc |